What Is Vir Biotechnology, Inc. (VIR) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Vir Biotechnology, Inc.'s intrinsic value is estimated at $4.52, suggesting the stock is overvalued at its current price of $9.72. With 9 out of 11 models flagging downside (-53.5% average return), the market may be pricing in unsustainable growth. Notably, EROIC sees the most upside at +27.9% (fair value: $12.43), while ML-RIV is the most conservative at -95.4% ($0.45). The spread between these extremes — +123.2% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About VIR?
11 of 13 models are currently active for VIR. Of these, 2 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates VIR's intrinsic value at $2.14, implying -78.0% downside from the current price. See which stocks rank higher →
How Does VIR Rank in Biological Products, (No Diagnostic Substances)?
Among 139 Biological Products, (No Diagnostic Substances) stocks, VIR ranks #14 by Quality of Company score. CirclFi's QOC score of 7.2/10 evaluates 32 fundamental signals. A score of 7.2 indicates above-average quality.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
Vir Biotechnology, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is VIR a Value Trap?
CirclFi's Value Trap algorithm assigns VIR a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Vir Biotechnology, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Vir Biotechnology, Inc.'s fundamental quality profile registers 7.2/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +123.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every VIR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across VIR's 11 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad